🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

ACBFF, ARRY, CHRS, COOL - 4 Stock Charts To Watch

Published 06/19/2018, 11:50 PM
Updated 07/09/2023, 06:31 AM
ARRY_old
-
CHRS
-
RGTPQ
-
ACB
-

Aurora Cannabis Inc (OTC:ACBFF), the second largest cannabis stock, had a 5-wave move up coming off a large base. I don’t think marijuana stocks are anywhere near done yet. Longer-term I think it can be played and that this is a 20-25-dollar stock at some point. What we’re seeing now is a run-up to resistance and a pullback. Tuesday was a bit of an up-day, ACBFF gaining 28 cents, or 4%, to 7.20, on 2.35 million shares. This needs to get through 7.90. If it gets through there, targets are 9 3/4-10, and then 12 1/2. Keep an eye on volume on this one.

Array BioPharma Inc (NASDAQ:ARRY) had a big bullish, engulfing bar on Tuesday, coming off the trend line and moving average, and breaking out at the close, jumping 1.50, or 9%, to 19.00, on 3.85 million shares. Short-term target is 21 1/2-22, and intermediate target 25-6.

Coherus BioSciences Inc (NASDAQ:CHRS), a swing trade of ours, may have broken out on Tuesday, gaining another 1.15, or 8%, to 16.40, on 1 million shares. This stock needs a follow-through. Note that the high was 16.95, and the high back in May was 17.05. So, it needs to get through that zone. The next targets are 20, and then 24.

PolarityTE Inc (NASDAQ:COOL) had a great day on Tuesday, making its way up 1.58, or 5.2%, to 31.88, on 820,823 shares traded. I really like the way its been acting since it broke out in early May. It ran up sharply, formed a falling wedge, and then the next run-up was interrupted by the Citron report. It can only do so much and could knock it down, but it snapped right back up on decent volume to retest the high at 33-331/4. If it gets through here, targets going forward are 38, and then 45.

Stocks on the long side included Aurora Cannabis Inc. (ACBFF), Canopy Growth Corporation (CGC), Akcea Therapeutics, Inc. (AKCA), Array BioPharma Inc. (ARRY), Arrowhead Pharmaceuticals, Inc. (ARWR), Audentes Therapeutics, Inc. (BOLD), Coherus BioSciences, Inc. (CHRS), Caladrius Biosciences, Inc. (CLBS), PolarityTE, Inc. (COOL), Cornerstone OnDemand, Inc. (CSOD), Evolus, Inc. (EOLS), Fate Therapeutics, Inc. (FATE), National CineMedia, Inc. (NCMI), Neptune Technologies & Bioressources Inc. (NEPT), Spark Therapeutics, Inc. (ONCE), Sarepta Therapeutics, Inc. (SRPT), and SolarWindow Technologies, Inc. (WNDW).

Watch video here.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.